PURPOSE: To determine the long-term outcome of patients afterallogeneic transplantation of T-cell depleted versus unmanipulated hematopoietic stem cell grafts with respect to incidence of GvHD and overall survival in 50 consecutive patients. METHODS: In this prospective phase II study utilizing biological randomization, 50 sibling donors were mobilized with G-CSF. Positive selection of CD34+ cells (Ceprate SC; CellPro, USA) was performed in good mobilizers (n = 25; group A), but not in poor mobilizers (n = 25; group B). Patients had hematological malignancies. Median patient age was 44 years (range, 19-57). Numbers of CD3+ cells were 0.5 ± 0.4 × 10(6)/kg in group A and 216 ± 127 × 10(6)/kg in group B. RESULTS:Hematological recovery was rapid in both groups. Patients in group A had no grade III-IV acute GvHD, whereas 6 out of 22 evaluable patients in group B had grade III-IV acute GvHD with fatal outcome in four cases (P < 0.01). Similarly, the incidence of chronic GvHD was lower in patients in group A (35 vs. 65%). However, there was a higher relapse rate in group A (11/25) versus group B (4/25, P < 0.05). At a follow-up of 10 years after transplantation, eight (32%) and 10 patients (40%) were relapse-free and alive in groups A and B, respectively. CONCLUSIONS: Risk factors for survival in a multivariate analysis were remission status prior to transplantation (CR vs. no CR), occurrence of acute and chronic GvHD, and relapse. The use of the CellPro device for CD34 positive selection per se did not have an influence on overall survival.
RCT Entities:
PURPOSE: To determine the long-term outcome of patients after allogeneic transplantation of T-cell depleted versus unmanipulated hematopoietic stem cell grafts with respect to incidence of GvHD and overall survival in 50 consecutive patients. METHODS: In this prospective phase II study utilizing biological randomization, 50 sibling donors were mobilized with G-CSF. Positive selection of CD34+ cells (Ceprate SC; CellPro, USA) was performed in good mobilizers (n = 25; group A), but not in poor mobilizers (n = 25; group B). Patients had hematological malignancies. Median patient age was 44 years (range, 19-57). Numbers of CD3+ cells were 0.5 ± 0.4 × 10(6)/kg in group A and 216 ± 127 × 10(6)/kg in group B. RESULTS: Hematological recovery was rapid in both groups. Patients in group A had no grade III-IV acute GvHD, whereas 6 out of 22 evaluable patients in group B had grade III-IV acute GvHD with fatal outcome in four cases (P < 0.01). Similarly, the incidence of chronic GvHD was lower in patients in group A (35 vs. 65%). However, there was a higher relapse rate in group A (11/25) versus group B (4/25, P < 0.05). At a follow-up of 10 years after transplantation, eight (32%) and 10 patients (40%) were relapse-free and alive in groups A and B, respectively. CONCLUSIONS: Risk factors for survival in a multivariate analysis were remission status prior to transplantation (CR vs. no CR), occurrence of acute and chronic GvHD, and relapse. The use of the CellPro device for CD34 positive selection per se did not have an influence on overall survival.
Authors: R Nakamura; E Bahceci; E J Read; S F Leitman; C S Carter; R Childs; C E Dunbar; R Gress; R Altemus; N S Young; A J Barrett Journal: Br J Haematol Date: 2001-10 Impact factor: 6.998
Authors: Jacek Toporski; Michael Garkavij; Jan Tennvall; Ingrid Ora; Katarina Sjögreen Gleisner; Josefina H Dykes; Stig Lenhoff; Gunnar Juliusson; Stefan Scheding; Dominik Turkiewicz; Albert N Békássy Journal: Biol Blood Marrow Transplant Date: 2009-07-08 Impact factor: 5.742
Authors: Aa Oyekunle; U Koehl; H Schieder; F Ayuk; H Renges; N Fehse; T Zabelina; B Fehse; T Klingebiel; A Sputtek; Ar Zander; N Kröger Journal: Cytotherapy Date: 2006 Impact factor: 5.414
Authors: Peter Lang; Johann Greil; Peter Bader; Rupert Handgretinger; Thomas Klingebiel; Michael Schumm; Paul-Gerhard Schlegel; Tobias Feuchtinger; Matthias Pfeiffer; Hans Scheel-Walter; Monika Führer; David Martin; Dietrich Niethammer Journal: Blood Cells Mol Dis Date: 2004 Nov-Dec Impact factor: 3.039
Authors: Alvaro Urbano-Ispizua; Ciril Rozman; Pedro Pimentel; Carlos Solano; Javier de la Rubia; Salut Brunet; Jaime Pérez-Oteyza; Christelle Ferrá; Javier Zuazu; Dolores Caballero; Joan Bargay; Alzira Carvalhais; Jose Luis Díez; Ildefonso Espigado; Adrián Alegre; Montserrat Rovira; Fernando Campilho; Jesús Odriozola; Miguel Angel Sanz; Jordi Sierra; Javier García-Conde; Emili Montserrat Journal: Blood Date: 2002-07-15 Impact factor: 22.113
Authors: Mark Ringhoffer; Markus Wiesneth; Stephanie Harsdorf; Richard F Schlenk; Anita Schmitt; Peter P Reinhardt; Margit Moessner; Wolfgang Grimminger; Thomas Mertens; Sven N Reske; Hartmut Döhner; Donald Bunjes Journal: Br J Haematol Date: 2004-08 Impact factor: 6.998
Authors: Stephanie J Lee; David Zahrieh; Edwin P Alyea; Edie Weller; Vincent T Ho; Joseph H Antin; Robert J Soiffer Journal: Blood Date: 2002-10-15 Impact factor: 22.113
Authors: Wolfgang A Bethge; Christoph Faul; Martin Bornhäuser; Gernot Stuhler; Dietrich W Beelen; Peter Lang; Matthias Stelljes; Wichard Vogel; Matthias Hägele; Rupert Handgretinger; Lothar Kanz Journal: Blood Cells Mol Dis Date: 2007-09-14 Impact factor: 3.039
Authors: Sebastian P Haen; Michael Schumm; Christoph Faul; Lothar Kanz; Wolfgang A Bethge; Wichard Vogel Journal: J Cancer Res Clin Oncol Date: 2015-08-14 Impact factor: 4.553